Life SciencesLiability
Contact

TL;DR

Biotech insurance for a clinical-stage company is built around directors and officers (D&O) coverage scaled to investor and governance exposure, clinical trial liability for active studies, employment practices for hiring growth, fiduciary for plan assets, cyber for clinical data, IP infringement defense, and product liability that activates at commercialization. Biotech general liability and biotech company insurance program structure differs at pre-IND, Phase 1, Phase 2/3, IPO-readiness, and commercial launch. We build to the stage and step the biotech D&O program up at each transition.

Biotech Insurance · Directors & Officers · Texas

Biotech insurance for clinical-stage companies. Phase 2 readout in 90 days, D&O renewal in 60.

Clinical-stage public biotech faces securities class actions on virtually every Phase 2/3 readout. Biotech directors and officers (D&O) insurance renewal pricing tracks market cap, trial stage, and recent disclosure history - and the wrong transactional D&O placement at IPO/SPAC can leave gaps that surface only after a stock drop.

We work with Texas biotech companies (UT Southwestern, MD Anderson, Baylor College of Medicine, Texas Medical Center spinouts) on biotech D&O architecture, clinical trial liability for active studies, CTA insurance schedules, biotech general liability, and products tower scaling at Phase 3.

Get my coverage reviewRun the MSA Decoder

Biotech Directors & Officers Insurance

Biotech directors and officers insurance is the highest-priority placement.

Biotech directors and officers (D&O) insurance is the load-bearing placement for any clinical-stage drug company. Biotech D&O has been the highest-frequency securities-class-action sector for the last decade. Every Phase 2 and Phase 3 readout is a disclosure event; every regulatory pause is a disclosure event; every collaboration termination is a disclosure event. Biotech D&O renewal pricing tracks market cap, recent disclosures, and pipeline concentration.

Sizing tracks funding stage: Series A pre-revenue private biotech at $1M-$5M; Series B / Series C at $5M-$15M; IPO-readiness operators step up to $25M-$50M+ for the transactional D&O placement that sits separate from the ongoing-renewal D&O; post-IPO clinical-stage public biotech baselines at $50M-$150M+ with Side A DIC + Side B + Side C structure and 7-year discovery periods on the runoff.

The IPO/SPAC transaction adds a second D&O placement: transactional D&O for the offering itself. This is separate from the regular renewal D&O and has its own retention, runoff structure, and tail mechanics. Mishandling the placement during the IPO window leaves gaps that materialize only when a post-IPO stock drop triggers a class action - and then both carriers can dispute coverage allocation. Best-practice: place both with the same carrier or carriers that have worked together; align retentions and policy years; stipulate which policy responds to which trigger event.

Problem 02 · Clinical trial liability

CTA insurance schedules are non-trivial.

Clinical trial agreements with sites and CROs typically require sponsor-side trial liability with $5M-$10M minimums, plus additional-insured wording for the site, CRO, and investigators. Most CTA insurance schedules are dense and inconsistent across institutions; bigger academic centers (UT Southwestern, MD Anderson, Baylor) have their own institutional schedules layered on top of standard language.

The sponsor / CRO / site indemnification dance gets contentious when a subject injury claim alleges study-design or protocol-execution failure - that can land in CRO E&O instead of sponsor trial liability. Coordination language in the CTA and on the COIs determines who pays first.

Problem 03 · Cyber for clinical PHI and IP

Cyber liability sizes on the dataset under management, not on company headcount.

A 50-employee biotech managing data from a 2,000-subject Phase 3 trial faces breach exposure proportional to the 2,000 subjects, not the 50 employees. The exposure includes HIPAA-regulated PHI through investigative sites, sponsor-confidential clinical and regulatory data, and patent-defining trade secrets (composition of matter, manufacturing process, formulation IP).

Most generalist cyber policies do not adequately respond to HIPAA-regulated PHI exposure, and the trade secret extension required for DMF and platform IP is rarely included by default. The placement requires a carrier with healthcare cyber appetite, sized to dataset.

Problem 04 · Renewal lapse risk

The most expensive losses come from operational misses, not from underwriting.

A D&O renewal that lapsed because nobody on the legal team tracked the policy expiration triggered a 90-day gap that an investor used as cause to renegotiate financing terms. We have read the post-mortem.

We build a renewal calendar with 90/60/30-day milestones, manage submissions through specialty markets, and produce a clear renewal recommendation that reflects clinical progress (Phase 1 readout, Phase 2 advancement, IPO/SPAC track activation) rather than rote year-over-year increases.

Carrier access

We place biotech programs through specialty life-sciences underwriters.

Generalist carriers will write a clinical-stage biotech and price it as a startup tech company. The placement looks fine on the COI. The placement fails at first clinical setback, when it turns out the D&O excluded SEC enforcement defense or the cyber under-sized PHI dataset.

Our placements run through carriers with dedicated biotech and life-sciences underwriting and, for IPO-stage and post-IPO operators, surplus-lines markets accessed through wholesale partners. We know which markets will write pre-clinical D&O at competitive terms vs which will only write post-Phase 2.

Programs anchored in Texas with broader placement across the major US life-sciences clusters - including the New Jersey pharma corridor and the North Carolina (RTP) cluster.

Pricing

Wondering what this typically costs?

Premium ranges for biotech D&O, CTL, cyber, and EPLI at each clinical stage from pre-IND through commercial launch.

See pricing guide →

Frequently asked

Common questions from clinical-stage biotech operators

What is biotech directors and officers insurance (biotech D&O)?

Biotech directors and officers (D&O) insurance is the specialty D&O placement for biotech and clinical-stage drug companies, covering directors, officers, and the entity for securities class actions, derivative suits, and regulatory enforcement. Biotech D&O has been the highest-frequency D&O claim sector for the last decade because clinical-stage public biotech faces securities class actions on virtually every Phase 2/3 readout. Coverage architecture differs at every stage: Series A pre-revenue private biotech operators bind at $1M-$5M; clinical-stage public biotech baselines at $10M-$50M; transactional D&O at IPO or SPAC adds a separate placement; post-IPO clinical-stage public biotech scales to $50M-$150M+ Side A DIC + B + C with 7-year discovery periods. The placement carriers active in biotech D&O are a narrow specialty set.

How much biotech directors and officers insurance does a clinical-stage company need?

Biotech D&O sizing tracks funding stage and disclosure exposure. Series A pre-IPO: $1M-$5M typical. Series B / Series C: $5M-$15M. IPO-readiness: step up to $25M-$50M+ for the transactional D&O placement separate from the ongoing-renewal D&O. Post-IPO clinical-stage public biotech: $50M-$150M+ with Side A DIC + Side B + Side C structure. Late-stage pre-IPO programs require 7-year discovery periods on the runoff. The biggest underwriting credit factors: clean prior-claims history, no FDA clinical hold history, no recent investigator-initiated study failures, and disclosure-policy documentation showing proactive 8-K filing cadence.

What insurance does a clinical-stage biotech need?

D&O is the highest priority - clinical-stage public biotech faces securities class actions on every Phase 2/3 readout. Plus clinical trial liability for active trials, products liability scaling at Phase 3, cyber for IP protection, and EPLI.

Why is biotech directors and officers insurance so expensive?

Biotech D&O is the most expensive D&O placement in the broader life-sciences segment because of three structural drivers: securities class action exposure tied to clinical readouts and regulatory news (clinical-stage biotech has been the highest-frequency D&O claim sector for a decade), disclosure complexity (Phase 2/3 readouts are routine disclosure events that produce stock movement which produces litigation), and concentrated plaintiff bar (NY-, CA-, MA-, and NJ-based plaintiff firms file a disproportionate share of biotech securities class actions). Limits scale with market cap and trial stage. The placement carriers active in biotech D&O are a narrow specialty set; generalist D&O carriers either decline or price at materially uncompetitive terms.

When does a biotech need biotech D&O at IPO or SPAC?

The IPO or SPAC transaction adds a SECOND D&O placement separate from the ongoing-renewal D&O: transactional D&O for the offering itself. This placement has its own retention, runoff structure, and tail mechanics. Mishandling the placement during the IPO window leaves gaps that materialize only when a post-IPO stock drop triggers a securities class action - and then both carriers can dispute coverage allocation. Best-practice structure: place both with the same carrier or with carriers that have worked together; align retentions and policy years; stipulate which policy responds to which trigger event in the placement documentation. Transactional D&O is typically placed 4-8 weeks before the offering.

What is clinical trial liability?

Coverage for bodily injury claims by clinical trial subjects arising from study participation. Most CTAs require sponsor-side coverage with $5M-$10M minimums; CRO and site indemnification dance against this policy.

Does the sponsor or the CRO carry clinical trial liability?

Typically the sponsor carries the trial-liability policy with the CRO and sites added as additional insureds. Allocation of injury claims between trial-liability, CRO E&O, and site malpractice depends on causation language.

When should a biotech start the D&O conversation?

At Series A or first board formation. Pre-financing biotech can place private-company D&O affordably; waiting until IPO/SPAC creates rushed transactional D&O placement at materially worse terms.

Is products liability needed before commercial launch?

Limited products is appropriate during clinical trials (the trial itself is a products exposure). Full products tower is needed at Phase 3 readout / NDA filing as the company prepares for potential commercial launch.

Next steps

Keep going.

Authoritative references

Primary regulatory sources for biotech insurance

Why operators choose this practice

  • Life sciences only

    Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.

  • All 50 US states

    Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.

  • End-of-day SLA

    Coverage review requests come back the same business day. MSA reads are typically half an hour or less.

  • Decoder + glossary

    Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.

Related deep-dives

Go deeper on the specific clauses and decisions that show up most.

Cost breakdown guide →Browse all clauses →MSA Decoder tool →CRO insurance practice →South San Francisco biotech corridor →California life sciences insurance →Massachusetts (Kendall Sq) →New Jersey pharma corridor →Clinical trial liability insurance →Laboratory insurance for in-house QC →Best biopharmaceutical insurance 2026 →

Free coverage review

A specialist will reach out by end of business day.

No marketing sequences, no list rental. Half-hour MSA reads are the standard.

Get my coverage review

A specialist will reach out by end of business day.

Your details only schedule the review. No marketing sequences, no list rental.